Screen glue-like compounds against every cancer cell line and publish it
Some drugs work by sticking two proteins together so one destroys the other. These are usually found by luck. A large systematic search, published openly, would find many more.
Molecular glue degraders (thalidomide analogues, indisulam) were discovered serendipitously. Modern discovery pairs a chemical library with degradation readouts (global proteomics, reporter panels) across genetically diverse lines, using E3 ligase knockouts to confirm mechanism. A precompetitive atlas of compound-to-degraded-protein pairs would map which of the roughly 600 human E3 ligases can be redirected and against which classes of target.
- The undruggable drivers · The proteins that drive most cancers, such as MYC, mutant p53 and most RAS variants, still have no good drug.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaDesign protein degraders small enough to get into the brain
Shares C4 Therapeutics, Nurix Therapeutics, Monte Rosa Therapeutics, Kymera Therapeutics.
- IdeaFind E3 ligases that only tumours have, and build degraders around them
Shares Nurix Therapeutics, Kymera Therapeutics, Proteomics & phosphoproteomics, PROTACs & molecular glues (targeted protein degradation).
- IdeaMolecular glues that break the MYC-MAX partnership
Shares C4 Therapeutics, Monte Rosa Therapeutics, Kymera Therapeutics, PROTACs & molecular glues (targeted protein degradation).
- IdeaAn open degrader consortium against every undruggable driver transcription factor
Shares Monte Rosa Therapeutics, Kymera Therapeutics, Secrecy and intellectual property block collaboration, PROTACs & molecular glues (targeted protein degradation).
- TechnologyMolecular glue discovery platforms
Shares C4 Therapeutics, Nurix Therapeutics, Monte Rosa Therapeutics, Kymera Therapeutics.
- IdeaUse antibodies to deliver protein-destroying drugs into the right cells
Shares Nurix Therapeutics, Kymera Therapeutics, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaDegraders for the fusion proteins that drive childhood sarcomas
Shares C4 Therapeutics, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.